Topical RM191A gel for chronic peripheral neuropathic pain: randomized, double-blind, placebo-controlled, crossover pilot study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Introduction Current pharmacotherapy options for neuropathic pain (NPP) are limited. RM191A is a novel copper-amino acid complex that mimics superoxide dismutase and has anecdotal evidence for fast-onset analgesia. The aim of this pilot randomized clinical trial (RCT) was to evaluate the safety and efficacy of a topical gel containing RM191A compared with placebo in adults with moderate-to-severe chronic peripheral NPP. Materials and methods This single-site study was conducted at an Australian pain clinic. Eligible patients were randomized to receive either active or placebo gel, applied four times daily to the painful site for 3 days, followed by a 4-day washout and crossover to the other gel. Co-primary outcomes were changes in the Numerical Pain Rating Scale (NPRS) scores for average pain from baseline to Days 1 and 3. Secondary outcomes included safety/tolerability and neuropathic pain characteristics. Results Twenty-seven participants (14 males, 13 females, mean age 67 ± 15 years) were screened, with 25 proceeding to randomization and 24 completing both treatment periods. No first-order ( p = 0.816) or second-order carryover effects ( p = 0.322) were detected. The Day 1 coprimary outcome was not significant ( p = 0.323), but there was a trend toward one-sided statistical significance for the Day 3 coprimary outcome ( p = 0.073). The mean reduction in NPRS Average Pain by Day 3 was significant for the active gel (–0.9 ± 1.6, p = 0.012) but not the placebo (–0.2 ± 1.7, p = 0.485). Post hoc analysis revealed the superiority of the active gel in participants with Douleur Neuropathique 4 (DN4) scores ≥4 ( n = 15, p = 0.047). The number needed to treat (NNT) for 50% pain reduction by Day 3 was 8 (95% CI: greater than 3.9). The active gel was more effective against burning pain, paroxysmal pain, and paraesthesia/dysesthesia than other types of NPP. There were no serious adverse events, while four (16%) participants reported mild skin irritation. Discussion This small pilot RCT found that 3 days of RM191A gel modestly reduced chronic peripheral neuropathic pain. The NNT of 8 compares favorably with topical lidocaine (14.5) and is similar to duloxetine (7.4) and gabapentinoids (8.9). Larger, longer studies in well-defined neuropathic pain populations are warranted. Clinical Trial Registration ANZCTRN 12617000206325. https://www.anzctr.org.au/
Fields of Study & Subjects
Pain Mechanisms and Treatments
Pain Management and Treatment
Anesthesia and Pain Management
Publication details
- Journal / source
- Frontiers in Pain Research
- Volume
- 7
- Pages
- 1772899–1772899
- Publication date
- 27 March 2026
- Language
- EN